These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7868336)

  • 1. Intravenous DHE and cost saving.
    Robbins L
    Headache; 1995 Jan; 35(1):50. PubMed ID: 7868336
    [No Abstract]   [Full Text] [Related]  

  • 2. Development and Evaluation of an Integrated Outpatient Infusion Care Model for the Treatment of Pediatric Headache.
    Shapiro HFJ; Sant J; Minster A; Antonelli RC
    Pediatr Neurol; 2022 Feb; 127():41-47. PubMed ID: 34959159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outpatient continuous intravenous dihydroergotamine for refractory headache.
    Charles JA
    Headache; 2005 Apr; 45(4):394-5. PubMed ID: 15836585
    [No Abstract]   [Full Text] [Related]  

  • 4. Reduced adverse event profile of orally inhaled DHE (MAP0004) vs IV DHE: potential mechanism.
    Cook RO; Shrewsbury SB; Ramadan NM
    Headache; 2009; 49(10):1423-34. PubMed ID: 19751370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous dihydroergotamine therapy for pediatric abdominal migraines.
    Raina M; Chelimsky G; Chelimsky T
    Clin Pediatr (Phila); 2013 Oct; 52(10):918-21. PubMed ID: 23820001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early and transient side effects of repetitive intravenous dihydroergotamine.
    Queiroz LP; Weeks RE; Rapoport AM; Sheftell FD; Baskin SM; Siegel SE
    Headache; 1996 May; 36(5):291-4. PubMed ID: 8682669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment of cluster headache with repetitive intravenous dihydroergotamine.
    Mather PJ; Silberstein SD; Schulman EA; Hopkins MM
    Headache; 1991 Sep; 31(8):525-32. PubMed ID: 1960057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Instead of expensive infusion therapy, ambulatory phytotherapy in tinnitus treatment].
    MMW Fortschr Med; 2001 Nov; 143(48):58. PubMed ID: 11770380
    [No Abstract]   [Full Text] [Related]  

  • 9. Is orally inhaled dihydroergotamine (DHE) equivalent in efficacy in migraine to intravenous DHE?
    Tfelt-Hansen P
    Headache; 2014 Feb; 54(2):383. PubMed ID: 24512579
    [No Abstract]   [Full Text] [Related]  

  • 10. Outcome and Cost of Inpatient Hospitalization for Intravenous Dihydroergotamine Treatment of Refractory Pediatric Headache.
    Nelson GR; Bale JF; Kerr LM
    Pediatr Neurol; 2017 Jan; 66():76-81. PubMed ID: 27847180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a monthly coverage maximum (drug-specific quantity limit) on the 5-HT1 agonists (triptans) and dihydroergotamine nasal spray.
    Hoffman L; Mayzell G; Pedan A; Farrell M; Gilbert T
    J Manag Care Pharm; 2003; 9(4):335-45. PubMed ID: 14613452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is the Generally Held View That Intravenous Dihydroergotamine Is Effective in Migraine Based on Wrong "General Consensus" of One Trial? A Critical Review of the Trial and Subsequent Quotations.
    Bekan G; Tfelt-Hansen P
    Headache; 2016 Oct; 56(9):1482-1491. PubMed ID: 27595607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exacerbation of SUNCT and SUNA syndromes during intravenous dihydroergotamine treatment: A case series.
    Lambru G; Shanahan P; Matharu M
    Cephalalgia; 2015 Oct; 35(12):1115-24. PubMed ID: 25667300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combination.
    Schran HF; Bitz DW; DiSerio FJ; Hirsh J
    Thromb Res; 1983 Jul; 31(1):51-67. PubMed ID: 6612697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of dihydroergotamine in healthy volunteers and in neurological patients after a single intravenous injection.
    Kanto J; Allonen H; Koski K; Koulu M; Lammintausta R; Mäntylä R; Kleimola T; Siirtola T
    Int J Clin Pharmacol Ther Toxicol; 1981 Mar; 19(3):127-30. PubMed ID: 7228454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dihydroergotamine suppositories in a headache clinic.
    Ward TN; Scott G
    Headache; 1991 Jul; 31(7):465-6. PubMed ID: 1774163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetics of dihydroergotamine in the beagle dog after a single intravenous injection and after a continuous intravenous infusion.
    Kanto J; Allonen H; Kleimola T; Mäntylä R
    Acta Pharmacol Toxicol (Copenh); 1980 Apr; 46(4):241-4. PubMed ID: 7368942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Acute uncomplicated diverticulitis - ambulatory treatment].
    Markun S
    Praxis (Bern 1994); 2014 May; 103(11):667-8. PubMed ID: 24846894
    [No Abstract]   [Full Text] [Related]  

  • 19. Low molecular weight heparin plus dihydroergotamine for prophylaxis of postoperative deep vein thrombosis.
    Sasahara AA; Koppenhagen K; Häring R; Welzel D; Wolf H
    Br J Surg; 1986 Sep; 73(9):697-700. PubMed ID: 3530367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orally inhaled dihydroergotamine: a review.
    Tepper SJ
    Headache; 2013 Sep; 53 Suppl 2():43-53. PubMed ID: 24024602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.